Evidence of bioequivalence and positive patient user handling of a tocilizumab autoinjector
Author:
Affiliation:
1. Roche Innovation Center, New York, NY, USA
2. Roche Products Ltd., Welwyn Garden City, UK
3. F. Hoffmann-La Roche Ltd., Basel, Switzerland
Funder
F. Hoffmann-La Roche Ltd
Publisher
Informa UK Limited
Subject
Pharmaceutical Science
Link
https://tandfonline.com/doi/pdf/10.1080/17425247.2019.1604678
Reference21 articles.
1. Usability of a new disposable autoinjector platform device: results of a formative study conducted with a broad user population
2. Usability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported experience
3. Adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study
4. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE)
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 administered by auto-injector or pre-filled syringe: a randomized, open‑label, single-dose phase I study;Expert Opinion on Biological Therapy;2024-06-21
2. Mitigating target interference challenges in bridging immunogenicity assay to detect anti-tocilizumab antibodies;Bioanalysis;2024-06-17
3. Pharmacokinetics and tolerability of prefilled syringe and auto-injector presentations of MSB11456: results of a randomized, single-dose study in healthy adults;Expert Review of Clinical Immunology;2023-02-15
4. Pharmacokinetics of a proposed tocilizumab biosimilar (MSB11456) versus US-licensed tocilizumab: results of a randomized, double-blind, single-intravenous dose study in healthy adults;Expert Review of Clinical Immunology;2023-02-13
5. Customer-centric product presentations for monoclonal antibodies;AAPS Open;2023-01-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3